Journal Top Ten
June 17, 2002
photo-5 photo-6 Related Drug: Avandia
Article: Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence That Rosiglitazone Does Not Cause Hepatic Dysfunction
Summary: An analysis of liver function in Type 2 diabetic patients at baseline and serially in 13 double-blind, 2 open-label active-controlled, and 7 open-label extension studies of rosiglitazone treatment conducted in outpatient centers throughout North America and Europe. The study comprised more than 6,000 patients agest 30 to 80 years old. Patients underwent liver function studies measuring liver enzyme levels over several months. According to the results, there was no evidence of hepatotoxic effects …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference
January 10, 2025 - Long Beach, CA
The Westin Long Beach
HarrisMartin's New Jersey Asbestos Litigation Conference
February 27, 2025 - New Brunswick, NJ
Hyatt Regency New Brunswick